Phaseline

Companies › Hua Medicine

Hua Medicine: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HMS1005
GLP-1 receptor agonist
–Phase 1Type 2 Diabetes–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07568678HMS1005Phase 1Type 2 DiabetesMetabolic and endocrineAug 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.